Olema Pharmaceuticals, Inc. (OLMA)

Several events have influenced OLMA's stock price over the past six months. Olema closed a public offering of common stock in November 2025, generating approximately $218.5 million. The stock reached a four-year high in December 2025 following an increased price target from Jefferies. In March 2026, the company reported its fourth quarter and full-year 2025 financial and operating results and announced preclinical data for Palazestrant and OP-3136 at the AACR Annual Meeting. Inducement grants were reported in April and May 2026. Olema announced plans to present initial clinical data for OP-3136 at the ASCO Annual Meeting and appointed Prakash Raman, Ph.D., to its Board of Directors in April 2026. The stock has increased by 157.55% from May 5, 2025, to May 1, 2026, and 226.8% over the past 12 months, with a six-month increase of 81.71%. However, year-to-date in 2026, the stock has decreased by 40.4%. The stock's 52-week high was $36.26 and its low was $3.89.

As a clinical-stage biopharmaceutical company without commercialized products, Olema Pharmaceuticals does not have discernible demand seasonality. The demand for its offerings is tied to the progress and success of its clinical trials and regulatory approvals, rather than seasonal consumer patterns.

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, particularly ER+/HER2- metastatic breast cancer. Their lead product candidate, palazestrant (OP-1250), is in Phase 3 clinical trials (OPERA-01 and OPERA-02) for ER+/HER2- metastatic breast cancer. They are also developing OP-3136, a KAT6 inhibitor, currently in Phase 1 clinical study.

Olema Pharmaceuticals is headquartered in San Francisco, California, and has operations in Cambridge, Massachusetts. The majority of its shareholders are based in the United States (approximately 90.1%), with smaller percentages from other countries including the United Kingdom, Australia, Luxembourg, Switzerland, Sweden, Ireland, Canada, China, Italy, Hong Kong, Norway, and South Korea.

Olema Pharmaceuticals has generally maintained a positive brand reputation due to advancements in clinical development. Analysts have a consensus rating of "Buy" or "Moderate Buy". The company's reputation has been bolstered by the progression of palazestrant through Phase 3 trials, the initiation of Phase 1 for OP-3136, successful fundraising efforts, and strategic collaborations. A potential negative event occurred in March 2026 when the company was investigated on behalf of investors. Insider selling of $1.0 million in shares could be perceived negatively. The company's GF Score™ of 38/100 indicates potential challenges in financial strength and profitability.

Olema Pharmaceuticals has 202 institutional owners and shareholders, holding 90,496,885 shares, representing approximately 37.71% of the company's stock. Major institutional shareholders include Bain Capital Life Sciences Investors, LLC, Paradigm Biocapital Advisors LP, Janus Henderson Group Plc, BlackRock, Inc., BVF Inc/il, Fmr Llc, The Vanguard Group Inc, Siren, L.L.C., Logos Global Management LP, and Cormorant Asset Management, LP. Public companies and retail investors own about 52.04% of the stock, while insiders hold approximately 10.25%. Insider activity in the past three months showed $1.0 million worth of shares sold, with no insider buying.